Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
- Biologic effect of salt inducible kinase (SIK) mechanism in firstpatient studies supports further progression of Toledo portfolio
- SIK2/3 inhibitorGLPG3970 generally safe and well-tolerated
- Study in psoriasispatientsshowsimprovement in PASI score at Week 6
- Study in ulcerative colitis (UC) patients shows signs of biologically important effects; does not translate to signal on Mayo score at Week 6
- No signal observed in rheumatoid arthritis (RA)study at Week 6
Mechelen, Belgium; 14July2021; 22.01 CET; regulated information – Galapagos NV(Euronext & Nasdaq: GLPG)reports topline results with GLPG3970 in three patientstudies.GLPG3970, the first product candidatefrom a broad portfolio of SIK inhibitor compounds, provides clinicaldatasupporting the role of SIK inhibition in inflammation. SIK is a novel target class discovered by Galapagos.
Galapagos evaluated GLPG3970, a proprietary salt inducible kinase (SIK) 2/3 inhibitor, in three randomized, placebo-controlled, double-blind studies: a Phase 1b study in patients with moderate to severe psoriasis and two Phase 2a studies in patients with moderate to severely active UC and RA. GLPG3970 or placebo were administered orally once-daily for 6 weeks. Main objectives were to evaluate the safety and tolerability of GLPG3970 as well as early signs of biologic and clinical effect.
Across the three studies, GLPG3970 was generally safe and well tolerated. There were no deaths nor serious adverse events, and the majority of treatment emergent adverse events (TEAEs) were mild or moderate in nature.
CALOSOMA study: Phase 1b trial in psoriasis
This study randomized 26 patients with moderate to severe psoriasis in a 3:2 ratio, GLPG3970 to placebo. Two out of 15 patients discontinued in the treatment arm (COVID-19 and pruritus) versus 1 out of 11 on placebo (psoriatic arthropathy).
At Week 6, four out of 13 patients on GLPG3970 had a PASI1 50 response, defined as at least a 50% improvement of baseline PASI, compared to none on placebo. Specifically, the four responders achieved 50%, 50%, 56%, and 77% improvement in their PASI scores from baseline, reaching statistical significance compared to placebo (p=0.002) at Week 6. Positive signals of clinical effect were also consistently observed for other endpoints, including affected Body Surface Area and physician and patient global assessment, versus placebo at Week 6.
SEA TURTLE study: Phase 2a trial in UC
This study randomized 31 biologic-naïve patients with moderate to severely active UC in a 2:1 ratio, GLPG3970 to placebo. One out of 21 patients discontinued in the active treatment arm (COVID-19) versus one out of 10 on placebo (QT abnormality at baseline).
At Week 6, positive signals were observed in patients on GLPG3970 on objective parameters such as endoscopy, histology, and fecal calprotectin. These findings did not translate in a differentiation from placebo on change from baseline total Mayo Clinic Score in this 6-week study (GLPG3970 -2.7, placebo -2.6). Seven out of 18 patients on GLPG3970 who underwent endoscopy at Week 6 met the criteria for Endoscopic Improvement, defined as a score of 0 or 1 on the endoscopic response score, compared to one out of 9 patients on placebo. The robustness of these signals will be further examined when additional efficacy and biomarker data become available later this year.
LADYBUG study: Phase 2a trial in RA
This study randomized 28 patients with moderate to severely active RA and an inadequate response to methotrexate in a 3:2 ratio, GLPG3970 to placebo. Three out of 16 patients discontinued in the treatment arm (COVID-19, ALT increase and physician decision) versus 2 out of 12 on placebo (COVID-19).
At Week 6, patients on GLPG3970 showed no differentiation from placebo on change from baseline DAS28 (CRP)2 response (GLPG3970 -1.29, placebo -1.24), nor on the majority of other efficacy endpoints.
Further development of Toledo product portfolio
GLPG3970 is the first compound from Galapagos’ broad portfolio of novel molecules to provide clinical evidence for the potential role of SIK inhibition in inflammation. Biomarker data from these signal-finding studies with GLPG3970 will be further analyzed for signature profiles. Our aim with the Toledo program is to explore this novel mode of action fully and bring forward improved molecules directed toward SIK2/3 as well as other SIK selectivity profiles. Galapagos currently has two compounds exhibiting SIK2/3 inhibition in preclinical development.
“We are excited to demonstrate, for the first time, important biologic and clinical effects with a SIK inhibitor in patients with inflammatory conditions. This is a major achievement when working on a novel mode of action target class. The CALOSOMA trial in psoriasis patients indicates clear proof of activity and the SEA TURTLE trial in ulcerative colitis patients provides encouraging results that support further development with Toledo compounds with improved pharmacology. In addition, these studies in patients confirm the safety and tolerability profile previously observed in healthy volunteers,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. “The GLPG3970 broad dataset is an important step forward, and we aim to apply key learnings from these studies to the further development of our Toledo portfolio of SIK inhibitors.”
Galapagos intends to submit study outcomes with GLPG3970 for publication at scientific conferences and in peer-reviewed medical journals.
“Toledo” is an extensive program with a novel target class, SIK, whose potential role in inflammation was discovered by Galapagos. The Toledo program aims to treat a broad range of autoimmune conditions with important unmet medical needs. The Toledo platform delivers small molecule inhibitors of SIK targets with different selectivity profiles. The most advanced compound, SIK2/3 inhibitor GLPG3970, has shown immunomodulatory activity in vitro preclinically and ex vivo clinically with what Galapagos believes is a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. SIK inhibition has previously shown encouraging preclinical activity in a range of inflammatory disease models.
GLPG3970 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.
Galapagos NV (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.
This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143
Senior Director Corporate Communications
+32 491 92 64 35
Director Executive Communications
+31 65 3591 999
Galapagos Forward-Looking Statements
Thispress release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to diﬀer materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG3970 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG3970 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties and that Galapagos’ estimations regarding its GLPG3970 development program and regarding the commercial potential of GLPG3970 as well as regarding its Toledo platform, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
1 Psoriasis Area and Severity Index; an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area
2 DAS28 is a RA Disease Activity Score based on a calculation that uses tender and swollen joint counts of 28 defined joints, the physician’s global health assessment and a serum marker for inflammation, such as C-reactive protein. DAS28 (CRP) includes the C-reactive protein score calculation
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Synchronoss Names Christina Gabrys Chief Legal Officer27.7.2021 22:05:00 CEST | Press release
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital products and platforms, today announced the appointment of Christina “Chrissy” Gabrys as Chief Legal Officer. Gabrys succeeds Ronald Prague who is stepping down after 15 years with the company to pursue other interests. In her new role, Gabrys will oversee all legal affairs for the company. “Ron has played a significant role in shaping the Synchronoss that we are today. His leadership in negotiating and closing customer agreements, completing acquisitions and the company’s other financial endeavors – including his contribution to the successful recent recapitalization of the company – has been invaluable and he will be greatly missed,” said Jeff Miller, President and CEO of Synchronoss. “I would like to thank Ron for all he’s contributed to the business. We will always consider him part of the Synchronoss family and wish him w
SBM Offshore signs FPSO Almirante Tamandaré contracts27.7.2021 18:37:16 CEST | Press release
July 27, 2021 SBM Offshore is pleased to announce it has signed contracts with Petróleo Brasileiro S.A. (Petrobras) for the 26.25 years lease and operation of FPSO Almirante Tamandaré. These contracts follow the signing of the binding Letter of Intent as announced on February 25, 2021. FPSO Almirante Tamandaré will be deployed at the Búzios field in the Santos Basin approximately 180 kilometers offshore Rio de Janeiro in Brazil. SBM Offshore is progressing with the design and construction using its industry leading Fast4Ward® program. Delivery of the FPSO is expected in the second half of 2024. CorporateProfile The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation. As of December 31, 2020, the Company employs approximately 4,570 people worl
Exel Industries :Third quarter 2020-2021 revenue : A sustained growth rate of 18.4%, in line with our expectations.27.7.2021 18:00:00 CEST | Press release
PRESS RELEASE July 27, 2021 Third quarter 2020-2021 revenue A sustained growth rate of 18.4%, in line with our expectations. Q3 revenue in €m2019 ‐ 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying99.6113.814.216.414.3%16.4%Sugar Beet Harvesters218.104.22.1689.3%39.9%Garden Watering and Spraying50.149.8-0.3-0.8-0.6%-1.6%Industrial Spraying38.85516.217.941.9%46.2%EXEL Industries Group210.4249.238.842.218.4%20.1% *like‐for‐like = at constant foreign exchange rates and scope 9-month revenue in €m2019 - 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying255.729236.342.114.2%16.5%Sugar Beet Harvesters53.863.81010.918.7%20.2%Garden Watering and Spraying89.3109.420.120.322.4%22.7%Industrial Spraying125.8169.243.43834.5%30.2%EXEL Industries Group524.7634.4109.8111.320.9%21.2% *like‐for‐like = at constant foreign exchange rates and scope Third quarte
Leasinvest Real Estate SA: Publication of a transparency notification27.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 27 July 2021 issued by AXA, shows a passive threshold overrun, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AXA in Leasinvest Real Estate has decreased to 13.44% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress AXA SA 25, Avenue Matignon, 75008 Paris, France TRANSACTION DATE: 19 July 2021 THRESHOLD DROPPED BELOW: 15% DENOMINATOR: 11,804,919 DETAILS OF THE NOTIFICAT
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2021 RESULTS27.7.2021 18:00:00 CEST | Press release
Almere, The Netherlands July 27, 2021, 6 p.m. CET Continued robust market demand fuels strong quarterly performance ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2021 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2020 Q1 2021 Q2 2021 New orders 298.0 410.6 515.7 Revenue 341.8 394.0 411.7 Gross profit margin % 48.3 49.5 48.1 Operating result 87.6 124.5 118.4 Operating result margin % 25.6 31.6 28.7 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 10.7 13.9 19.3 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.3) (3.0) (3.0) Net earnings 74.1 122.5 108.4 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 77.4 125.5 111.4 New orders of €516 million for the second quarter 2021 increased by 73% compared to the same
Vastned Belgium: Interim half-yearly report for the first half of 202127.7.2021 18:00:00 CEST | Press release
High stable collection rate (97.9%) of rental income during the first half of 2021. Occupancy rate during the first half of 2021 (97.4%) increased by 1.2% compared to 31 December 2020. Limited debt ratio of 28.6%, in line with 31 December 2020 (28.5%). € 34.7 million of unused credit facilities available. Decrease in the fair value of the existing real estate portfolio (-2.2%) compared to the previous financial year. Management focus in 2021 mainly on the timely collection of rental income and maintaining a strong occupancy rate. Full press release: Attachment VB_Interim half-yearly report for the first half of 2021
ASM INTERNATIONAL N.V. NOMINATES TWO NEW SUPERVISORY BOARD MEMBERS27.7.2021 17:45:00 CEST | Press release
Almere, The Netherlands July 27, 2021, 5.45 p.m. CET ASM INTERNATIONAL N.V. NOMINATES TWO NEW SUPERVISORY BOARD MEMBERS ASM International N.V. (Euronext Amsterdam: ASM) today announces the nomination of Pauline van der Meer Mohr and Adalio Sanchez for appointment to its Supervisory Board. The Supervisory Board proposes to appoint Mrs. Pauline van der Meer Mohr and Mr. Adalio Sanchez as members of the Supervisory Board. Their appointment will be proposed to shareholders during an Extraordinary General Meeting (EGM). The EGM is planned for September 29, 2021, and further details of the EGM will be announced in due course. Pauline van der Meer Mohr (1960) is a seasoned non-executive director and brings over 35 years of experience in leadership positions in multinational businesses and academia. She started her career as a lawyer before making a career at the Royal Shell group from 1989 to 2004. After that she became the Group HR Director of TNT N.V. followed by fulfilling the role of Seni